Key Details
Price
$0.67Annual ROE
-207.47%Beta
0.64Events Calendar
Next earnings date:
Apr 1, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Apr 1, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer.
After reaching an important support level, Xilio Therapeutics, Inc. (XLO) could be a good stock pick from a technical perspective. XLO recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the SITC Annual Meeting
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors.
Xilio (XLO) surges by 79.8% in just one month following the announcement of an exclusive worldwide licensing agreement with Gilead Sciences for the development of XTX301 for advanced solid tumors.
Xilio Therapeutics (NASDAQ: XLO ) stock is rocketing higher on Thursday after the clinical-stage biotechnology company signed an exclusive license agreement with Gilead Sciences (NASDAQ: GILD ). This agreement has Gilead taking over the development and commercialization responsibilities of Xilio Therapeutics' XTX301.
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023.
FAQ
- What is the ticker symbol for Xilio Therapeutics?
- Does Xilio Therapeutics pay dividends?
- What sector is Xilio Therapeutics in?
- What industry is Xilio Therapeutics in?
- What country is Xilio Therapeutics based in?
- When did Xilio Therapeutics go public?
- Is Xilio Therapeutics in the S&P 500?
- Is Xilio Therapeutics in the NASDAQ 100?
- Is Xilio Therapeutics in the Dow Jones?
- When was Xilio Therapeutics's last earnings report?
- When does Xilio Therapeutics report earnings?
- Should I buy Xilio Therapeutics stock now?